Repoopulation Remedy

Transplanting synthetic stool made of beneficial microbes cures deadly diarrheal infections in two patients.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, GRAY'S ANATOMYPhony poo containing 33 isolates of commensal microbes cured two patients suffering from recurrent intestinal infections of Clostridium difficile after doctors infused the fake fecal matter into their colons during a colonoscopy. The successful insertion of synthetic stool, published today in Microbiome, provides hope for a much-needed treatment against diarrhea-causing, often drug-resistant infections by C. difficile, for which conventional fecal transplant therapies have failed to develop.

“Fecal bacteriotherapy, or ‘stool transplant,’ . . . has shown promising results in preliminary studies, but concerns about pathogen transmission, patient acceptance, and inability to standardize the treatment regimen remain,” the authors wrote in the study. “This proof-of-principle study demonstrates that a stool substitute mixture comprising a multi-species community of bacteria is capable of curing antibiotic-resistant C. difficile colitis.”

The two patients involved in the study suffered from a hyper-virulent strain of C. difficile known as ribotype 078, which was unscathed by courses of the antibiotic metronidazole and the “last resort” antibiotic, vancomycin. But 2 to 3 days after the synthetic stool transplant, both patients rid their symptoms and remained symptom-free for at least 6 months. Moreover, DNA sequencing of the patients’ stool samples taken ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Beth Marie Mole

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours